INSEMPRA
25.5.2023 08:01:30 CEST | Business Wire | Press release
Insempra, a biology-powered company enabling businesses to make superior products with nature, and Fibers365, a company offering chemical-free processed fibers and substrates from annual plants, today announce that they are working together to develop and scale sustainable second-generation (2G) feedstock for the commercial production of fermentation-based ingredients.
2G feedstocks, also known as lignocellulosic feedstocks, are a key area of research and development in biotechnology as the industry is facing a growing need in the application of these in fermentation processes. Fast moving consumer good companies, for example, are demanding sustainably procured raw materials. By utilizing agricultural residues, 2G feedstock has the potential to reduce greenhouse gas emissions by replacing fossil-based and de-forestation-based ingredients and consumer products. Insempra has built a broad toolbox to use feedstocks derived from agricultural wastes and also upcoming intermediates originating from carbon capture methods.
The Fibers365 patented, modular, farm level Steam Fiber Plants allow the competitive extraction of functional cellulosic fibers, lignin and sugars from multi feedstock non-wood biomass. The sugars, currently used for the generation of biogas, can be further valorized by producing high-value products via fermentation for various industrial applications.
“By working together with Insempra, we are combining our unique 2G feedstock derived from agricultural side streams with the highly advanced fermentation technology platform needed to scale and make this sustainable feedstock accessible to broader applications.” said Stefan Radlmayr, Founder and Managing Partner of Fibers365.
One of the primary challenges with 2G feedstocks is the intrinsic material stability of lignocellulosic materials. Unlike first-generation feedstocks (e.g., those derived from beets, corn, sugarcane), which contain easily accessible sugars, lignocellulosic biomass is composed of complex structures that require pre-treatment and enzymatic hydrolysis to release the sugars. Developing efficient and cost-effective pre-treatment methods and robust enzymatic cocktails for biomass deconstruction is a key challenge in the adoption of 2G feedstocks at scale.
Insempra has successfully tested Fibers365’s 2G feedstock derived from agricultural waste streams (e.g., wheat straw) with its proprietary fermentation technology platform. Insempra is using this technology for the development of speciality lipids for application in the beauty and personal care as well as nutraceuticals and food industries. In addition to speciality lipids, Insempra is also working on the production of protein fibers and high-value functional ingredients with 2G feedstocks from agricultural waste.
“Using second-generation feedstocks in our manufacturing processes has always been one of our priorities as a biology-powered business. We are tremendously excited about the potential this technology not only has for our businesses, but for the whole industry.” said Jens Klein, CEO & Founder of Insempra.
By working together, Insempra and Fibers365 tackle the challenge of scaling and aim to maximize the potential of 2G feedstocks to support their mission to manufacture at scale in collaboration with nature, thereby contributing to a more sustainable and circular future.
About Insempra
Insempra GmbH, Munich (Germany), is a biology-powered company enabling businesses to make superior products with nature. We combine bioscience and technology to grow matter for new and better products.
For too long, businesses have relied on chemical industrialization processes and petrochemicals, depleting our planet’s limited resources. That’s why we are committed to drive the regenerative revolution to manufacture at scale in collaboration with nature.
Led by a hand-picked team of biologists, technologists, and entrepreneurs with rebel hearts, Insempra is here to create a new school of thought and collective action. The time to restore the balance between people and the planet is now. We don't wait for change. We do what needs to be done to grow a better future.
Learn more about Insempra at insempra.bio
About Fibers365
Fibers365 GmbH, Lenningen (Germany), offers a unique, multi-feedstock biomass processing technology for annual plants to provide functional, competitive non wood biomass products such as virgin fibers for paper, packaging and textile applications as well as high value biopolymer and fertilizer side streams, produced with carbon neutral bioenergy. The products are extracted from agricultural residues such as straw by a chemical-free, regional, farm level steam explosion pulping technology, allowing easy separation of cellulosic fibers from sugars, lignin, organic acid and minerals. The use of annually regrown plants allows to compensate CO2 emissions from processing and product consumption almost instantly, by closing a yearly carbon loop.
Learn more about Fibers365 at fibers365.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005793/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
